211
- Zhou Z, Xia Y, Bandla S, Zakharov V, Wu S,
Peters J, Godfrey TE, Sun J (2014) Vitamin D
receptor is highly expressed in precancerous
lesions and esophageal adenocarcinoma with
significant sex difference. Human Pathol
45:1744–1751. https://doi.org/10.1016/j.
humpath.2014.02.029
- Boonstra JJ, van Marion R, Douben HJ,
Lanchbury JS, Timms KM, Abkevich V, Tilanus
HW, de Klein A, Dinjens WN (2012) Mapping
of homozygous deletions in verified esophageal
adenocarcinoma cell lines and xenografts.
Genes Chromosomes Cancer 51:272–282.
https://doi.org/10.1002/gcc.20952
- Soutto M, Peng D, Razvi M, Ruemmele P,
Hartmann A, Roessner A, Schneider-Stock R,
El-Rifai W (2010) Epigenetic and genetic
silencing of CHFR in esophageal adenocarci-
nomas. Cancer 116:4033–4042. https://doi.
org/10.1002/cncr.25151
- Bandla S, Peters JH, Ruff D, Chen SM, Li CY,
Song K, Thoms K, Litle VR, Watson T,
Chapurin N, Lada M, Pennathur A, Luketich
JD, Peterson D, Dulak A, Lin L, Bass A, Beer
DG, Godfrey TE, Zhou Z (2014) Comparison
of cancer-associated genetic abnormalities in
columnar-lined esophagus tissues with and
without goblet cells. Ann Surg 260:72–80.
https://doi.org/10.1097/
SLA.0000000000000424
- Zhang K, Wu X, Wang J, Lopez J, Zhou W,
Yang L, Wang SE, Raz DJ, Kim JY (2016)
Circulating miRNA profile in esophageal ade-
nocarcinoma. Am J Cancer Res 6:2713–2721
- Goh XY, Rees JR, Paterson AL, Chin SF,
Marioni JC, Save V, O’Donovan M, Eijk PP,
Alderson D, Ylstra B, Caldas C, Fitzgerald RC
(2011) Integrative analysis of array-compara-
tive genomic hybridisation and matched gene
expression profiling data reveals novel genes
with prognostic significance in esophageal ade-
nocarcinoma. Gut 60:1317–1326. https://
doi.org/10.1136/gut.2010.234179
- Silvers AL, Lin L, Bass AJ, Chen G, Wang Z,
Thomas DG, Lin J, Giordano TJ, Orringer
MB, Beer DG, Chang AC (2010) Decreased
selenium-binding protein 1 in esophageal ade-
nocarcinoma results from posttranscriptional
and epigenetic regulation and affects chemo-
sensitivity. Clin Cancer Res 16:2009–2021.
https://doi.org/10.1158/1078-0432.
ccr-09-2801
- Obulkasim A, Ylstra B, van Essen HF, Benner
C, Stenning S, Langley R, Allum W,
Cunningham D, Inam I, Hewitt LC, West NP,
Meijer GA, van de Wiel MA, Grabsch HI
(2016) Reduced genomic tumor heterogeneity
after neoadjuvant chemotherapy is related to
favorable outcome in patients with esophageal
adenocarcinoma. Oncotarget 7:44084–44095.
https://doi.org/10.18632/oncotarget.9857
- Aichler M, Motschmann M, Jutting U, Luber
B, Becker K, Ott K, Lordick F, Langer R, Feith
M, Siewert JR, Walch A (2014) Epidermal
growth factor receptor (EGFR) is an indepen-
dent adverse prognostic factor in esophageal
adenocarcinoma patients treated with cisplatin-
based neoadjuvant chemotherapy. Oncotarget
5:6620–6632. https://doi.org/10.18632/
oncotarget.2268
- Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X
(2013) Association of mitochondrial DNA
copy number in peripheral blood leukocytes
with risk of esophageal adenocarcinoma.
Carcinogenesis 34:2521–2524. https://doi.
org/10.1093/carcin/bgt230
- Lee S, Han MJ, Lee KS, Back SC, Hwang D,
Kim HY, Shin JH, Suh SP, Ryang DW, Kim
HR, Shin MG (2012) Frequent occurrence of
mitochondrial DNA mutations in Barrett’s
metaplasia without the presence of dysplasia.
PLoS One 7:e37571. https://doi.
org/10.1371/journal.pone.0037571
- Geppert CI, Rummele P, Sarbia M, Langer R,
Feith M, Morrison L, Pestova E, Schneider-
Stock R, Hartmann A, Rau TT (2014) Multi-
colour FISH in esophageal
adenocarcinoma-predictors of prognosis inde-
pendent of stage and grade. Br J Cancer
110:2985–2995. https://doi.org/10.1038/
bjc.2014.238
- Ismail A, Bandla S, Reveiller M, Toia L, Zhou
Z, Gooding WE, Kalatskaya I, Stein L, D’Souza
M, Litle VR, Peters JH, Pennathur A, Luketich
JD, Godfrey TE (2011) Early G(1) cyclin-
dependent kinases as prognostic markers and
potential therapeutic targets in esophageal ade-
nocarcinoma. Clin Cancer Res 17:4513–4522.
https://doi.org/10.1158/1078-0432.
ccr-11-0244
- Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F,
Ohtsu A, Omuro Y, Satoh T, Aprile G,
Kulikov E, Hill J, Lehle M, Ruschoff J, Kang
YK, To GATI (2010) Trastuzumab in combi-
nation with chemotherapy versus chemother-
apy alone for treatment of HER2-positive
advanced gastric or gastro-esophageal junc-
tion cancer (ToGA): a phase 3, open-label,
randomised controlled trial. Lancet 376:687–
697. https://doi.org/10.1016/
S0140-6736(10)61121-X
- Almhanna K, Meredith KL, Hoffe SE, Shridhar
R, Coppola D (2013) Targeting the human
epidermal growth factor receptor 2 in esopha-
geal cancer. Cancer Control 20:111–116
DNA Copy-Number in Esophageal Adenocarcinoma
